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Growth control: Action mouse
J.M.W. Slack
A recently described knockout mouse has abnormally
large muscles. The phenotype suggests that the ablated
product, growth differentiation factor 8 or ‘myostatin’,
may be one of the long sought inhibitors that control
the growth of individual tissues and organs. 
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The problem of the control of growth is one of the last
unsolved mysteries of animal development. It is rarely per-
ceived as a problem, because much of the excitement of the
last 15 years has been concerned with the mechanisms of
regional specification in early embryos. During this period,
it has been usual to dismiss growth as ‘merely’ the increase
in the size of structures that were laid down in miniature at
an early stage of development. But it is precisely because
the early rudiments of body parts are very small, and the
adult size is very big, that a real problem emerges: the
slightest error in the factor of expansion of one body part
relative to the others would create a serious disproportion.
So how is the growth of the different body parts coordi-
nated so that they produce a harmonious whole?
This question has exercised numerous thinkers over the
years and an idea that keeps on surfacing is that of the cir-
culating tissue-specific growth inhibitor [1]. This is an
idea so elegant that it seems to compel belief despite a
certain shortage of evidence in its favour. But a recent
paper reporting the phenotype of a ‘knockout’ mouse with
a targeted mutation in the gene encoding growth differen-
tiation factor 8 — ‘myostatin’ — may provide just such
evidence [2]. These mice have muscles almost twice the
size of their wild-type littermates — indicating that they
lack a crucial growth inhibitor.
The proposition is that each tissue produces an inhibitor,
and the total output of inhibitor from the tissue is propor-
tional to its volume. The inhibitor diffuses freely and is
removed by degradation which takes place all over the
body. As it is produced by the specific tissue and is
removed by the whole body, the steady-state concentra-
tion of the inhibitor provides a measure of the volume of
the tissue relative to the volume of the whole body. Too
little tissue and the inhibitor is in deficit, so the growth
rate increases. Too much tissue and the inhibitor is in
excess, so no more growth occurs until the whole body can
catch up (Figure 1a,b).  
The critical predictions of this model relate to the behav-
iour of grafts of small organs into large hosts or vice versa.
In principle, a small, or young, graft inserted into a full
grown host, in place of the corresponding host organ
(Figure 1d), should rapidly expand to normal adult size.
By contrast, if such a graft is added to, rather than replac-
ing, the host organ (Figure 1f), then its growth should be
suppressed. Likewise, an adult organ grafted into a young
host should not grow (Figure 1c) and should be able to
suppress the continued growth of an endogenous organ of
the same type (Figure 1e). Unfortunately the data from
tissue grafting is often inconclusive, as even in syngeneic
animals the growth of a graft can be greatly dependent on
vascularisation and other nutritional problems. Further-
more, much of the existing data were gathered before
immune rejection was properly understood, so this too is
often a complicating factor. 
Figure 1
The specific feedback inhibition model. (a,b) In normal animals, the
level of inhibition keeps the tissue volume a constant proportion of the
whole body. (c,e) Large grafts to small animals cause the level of
inhibitor to accumulate and to prevent growth of the tissue. (d) A
small replacement graft in a large host. Here, the inhibitor is at a low
steady-state level and the graft will grow rapidly. (f) A small additional
graft in a large host. Here, the inhibitor is at slightly above normal
levels due to the augmentation of the tissue and so the graft should
grow a little slower than the animal. Tissue is shown in green and
inhibitor in purple.
(c)  Large graft to small host
(e)  Additional large graft
(a)  Small animal (b)  Large animal
(d)   Small graft to large host
(f)  Additional small graft
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What results there are suggest that the systemic inhibition
model may apply in certain cases but not in all. A contrary
example is provided by careful studies, carried out in the
1920s, of transplanted eyes between large and small species
of salamander. These revealed complete donor autonomy,
suggesting that there is no systemic control except for an
effect of the general nutritional state of the host [3,4]. For
the organs that do seem to follow the model to some
extent, probably the best studied example is the liver [5]. It
is well known that removal of part of the liver causes rapid
compensatory growth of the remainder. The effect must be
due to some substance in the blood, as it can be transmitted
between animals whose circulations have been joined. The
effects of transplantation also follow the model for those
graft combinations that have been investigated. When a
small liver is transplanted to a large host, then it will grow
much faster than the normal rate until it has gained a size
proportional to the host. Conversely, if a large liver is
grafted to a small host, then its growth is suspended until
the whole animal has caught up [6].
Another case where there is at least some systemic growth
control is the kidney. Removal of one kidney causes rapid
hypertrophy of the other. Some of the graft combinations
have been examined in the context of human organ trans-
plantation. A child’s kidney grafted into an adult grows
quickly, while an adult’s kidney grafted into a child
remains the same size. Restoration of a kidney that was
previously removed causes shrinkage of the contralateral
hypertrophic kidney back to normal size. However, the
addition of a third kidney cannot shrink the other two
below the normal size, so it seems that hypertrophic growth
can be shrunk more readily than can normal growth [7]. 
What is actually happening when an organ grows? There
may be an increase in cell size, or in cell number, or in the
number of structural-proliferative tissue units — for
example, the lobules of the liver or the nephrons of the
kidney — or in extracellular material and tissue fluid. Any
particular example of size change will show a combination
of these processes. The control of cell size is very poorly
understood, and what is known is mainly in the context of
metabolic events such as fat deposition. A factor that is
known to correlate closely to overall size is ploidy, with an
approximate doubling of cell size for each doubling of
chromosome complement. Polyploid cells do exist in the
liver and account for some increase in  cell size, but it
seems most unlikely that all changes in cell size are due to
polyploidy [8]. 
The control of cell division is understood rather well in
terms of the molecular biology of the cell cycle, or the
action of growth factors on tissue culture cells, but it is not
well understood in vivo. There is certainly very active cell
division in the regenerating liver or hypertrophic kidney,
and in the case of the liver it seems clear that circulating
hepatocyte growth factor is an important mitogenic stimu-
lus. The number of proliferative units is usually thought
to stay the same during hypertrophic growth of the liver or
kidney, but it has been shown that kidneys can increase
their nephron number if the other kidney is removed
during the normal period of nephron increase, which is
about the first 50 days after birth in the case of rats [9].
In no case is the identity of the putative tissue-specific
inhibitors known. It has never really been clearly estab-
lished to what extent the systemic regulators are specific
growth factors and to what extent they are normal metabo-
lites whose concentration depends on the organ size. It
seems well established that hepatocyte growth factor is an
important factor stimulating cell division in the regenerat-
ing liver, but its source lies outside the liver, and the iden-
tity of the signal from the liver that initially activates its
expression and release is still not known.
So is myostatin a good candidate for a tissue-specific
inhibitor? The sequence of this protein, a novel member
of the transforming growth factor b superfamily of growth
factors, is reported in the same paper as the targeted muta-
tion of the gene in mouse [2]. The gene is active from
embryonic day 9.5, and is expressed mainly in the devel-
oping myotomes. Expression continues as the skeletal
muscle differentiates and persists into post-natal life. At
present, there is no information about the biological activ-
ity of myostatin from tissue culture or other in vitro
systems, so the functional information comes just from the
phenotype of the knockout mouse. The mutant mice are
about 30% larger than wild-type or heterozygous litter
mates, and this difference is entirely due to a substantial
increase (approximately doubling) in the weight of skele-
tal muscle. The DNA content of the enlarged muscles is
increased showing that the increased size is partly due to
an increase in the number of nuclei, and hence in the
number of myoblasts contributing to the muscle fibres.
There is also some increase in fibre size as measured both
from observations of fibre diameter and as deduced from
the protein:DNA ratio.
To appreciate the significance of these results, it is worth
briefly reviewing the normal mode of development of
skeletal muscle [10]. In the embryo, myoblasts are
formed from the myotomes of the somites. Some of these
differentiate in situ, whereas others migrate into the
limbs, body wall and other regions. Myoblasts proliferate
for a while and then fuse with one another to form the
multinucleate fibres characteristic of skeletal muscle.
After fusion, neither the fibres nor the nuclei within them
can divide any further. During the growth of the animal,
however, there is an increase in the number of fibres per
muscle. These derive from a population of mononucleate
‘satellite cells’, presumably derived from the embryonic
myoblasts, that persists into adult life. During growth, the
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neither the fibres nor the nuclei within them can divide
any further. During the growth of the animal, however,
there is an increase in the number of fibres per muscle.
These derive from a population of mononucleate ‘satellite
cells’, presumably derived from the embryonic myoblasts,
that persists into adult life. During growth, the satellite
cells continue to divide and to form new myotubes,
accounting for the increase in the number of fibres [11].
After cessation of whole animal growth, some satellite
cells persist and are responsible for muscle regeneration
following tissue damage. During normal growth, in addi-
tion to the formation of new fibres, there is also a consider-
able enlargement of existing fibres, without any increase
in the number of nuclei. The increase in muscle size that
can be achieved by exercise is also entirely due to an
increase in fibre size, not to an increase in cell division or
fibre number. 
From the phenotype of the knockout mouse, we can
deduce that myostatin normally operates as some sort of
inhibitor, and that it probably represses both the number
of myoblast divisions and, to some extent, the degree of
fibre enlargement. The identification of a molecule that
definitely affects cell division in vivo is interesting. Even
more significant is the effect on cell size, as the control of
cell size is not understood at all, and this may represent a
tool for commencing some novel experimental studies.
Most exciting of all would be a potential role for myostatin
as a systemic inhibitor responsible for regulating the pro-
portion of muscle in the body, following the specific feed-
back inhibition model. The first step in investigating this
would be to find whether it circulates in the blood, and
whether production of myostatin by one muscle can affect
growth in another. If myostatin is a circulating systemic
inhibitor then its discovery will represent a real molecular
breakthrough into the problem of growth control, and
future studies could open up one of the darkest and most
mystifying corners of developmental biology.
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